Ascletis Pharma Inc.
1672
Ранг среди акций
#10745
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Цена акции
$0.70283519
Рыночная капитализация
$737.74M
Изменение (1 день)
-7.39%
Изменение (1 год)
-39.41%
Страна
CN
Торговля Ascletis Pharma Inc. (1672)
Категория
Healthcare
История цены акций Ascletis Pharma Inc. (1672)
Наивысшая цена закрытия: $0.92 2026-10-01
Наименьшая цена закрытия: $0.60 2019-11-01
Наименьшая цена закрытия: $0.60 2019-11-01
История цены акций Ascletis Pharma Inc. с 2019 по 2026
Годовая динамика цены акций
| Год | Результативность |
|---|---|
| 2026 (TTM) | -10.71% |
| 2025 | 759.36% |
| 2024 | 9.90% |
| 2023 | -65.45% |
| 2022 | 11,939.80% |
| 2021 | -98.81% |
| 2020 | -40.55% |
| 2019 | 0.00% |
Цена акций похожих компаний или конкурентов
| Компания | Цена акций | Изменение 1г% | Страна |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
